Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Despite mixed phase 3 showing, Apellis hopes to push eye disorder drug past FDA's finish line
Orchard picks an apple from Novartis' field with new chief technical officer
Louisiana revokes licenses from 7 nursing homes after Ida evacuation failures cost lives
Biogen CEO blames Aduhelm’s rocky launch on 'too much confusion, misinformation and controversy'
Cardiff reveals early data on challenger to Amgen's KRAS crown
Acorda slashes jobs again as generics hamper sales of MS drug
Sanford Health receives $350M for virtual care center to support rural health
COVID-19 tracker: Moderna's combo shot could hit clinic within a year; AZ criticizes booster rollout
Pediatric teletherapy provider DotCom Therapy raises $13M backed by LRVHealth, OSF Ventures
AstraZeneca's COVID-19 shot joins the list of vaccines flagged for rare Guillain-Barre syndrome
Centessa eyes registration in hemophilia as SerpinPC shows reduction of bleeding in phase 2 study
HHS aims to use value-based care payment models to lower drug prices

Featured Story

Despite mixed phase 3 showing, Apellis hopes to push eye disorder drug past FDA's finish line

By Noah Higgins-Dunn

Apellis Pharmaceuticals’ pegcetacoplan posted mixed results in two late-stage trials studying the C3 inhibitor in patients living with geographic atrophy (GA). Despite the mixed showing, CEO Cedric Francois thinks the med's performance was strong enough to warrant an FDA nod.

Orchard picks an apple from Novartis' field with new chief technical officer

By Kyle LaHucik

Gene therapy biotech Orchard Therapeutics has picked a shiny apple from Novartis, bringing Nicoletta Loggia, Ph.D. on as chief technical officer after a 17-year career at the Swiss pharma. Loggia previously served as global head of cell and gene therapies for Novartis—a high profile part of the pharma's business that in recent years has launched Zolgensma.

Louisiana revokes licenses from 7 nursing homes after Ida evacuation failures cost lives

By Dave Muoio

All seven nursing homes evacuated hundreds of residents to a single overcrowded facility, where surveyors observed unacceptable care and faced threats from ownership, according to the state health department.

Biogen CEO blames Aduhelm’s rocky launch on 'too much confusion, misinformation and controversy'

By Eric Sagonowsky

Before Biogen scored an FDA approval for Alzheimer's drug aducanumab, the company probably hoped its launch would go much smoother than the last three months have been. It turns out Biogen's CEO Michel Vounatsos is willing to say so publicly.

Cardiff reveals early data on challenger to Amgen's KRAS crown

By Annalee Armstrong

Amgen has already won the KRAS race by getting Lumakras across the finish line, but Cardiff Oncology has just rolled out some early data for a follow-on candidate showing partial responses and extended survival without disease progression compared to standard of care.

Acorda slashes jobs again as generics hamper sales of MS drug

By Kyle LaHucik

Acorda Therapeutics is restructuring yet again as sales for its multiple sclerosis and Parkinson's drugs continue to fall below expectations. The pharma is cutting 15% of its workforce after already reducing headcount by 16% in January.

Sanford Health receives $350M for virtual care center to support rural health

By Anastassia Gliadkovskaya

The virtual care center will serve patients in Sanford Health’s network, and will also be the home base of several innovation, education and research initiatives aimed at advancing digital healthcare.

COVID-19 tracker: Moderna's combo shot could hit clinic within a year; AZ criticizes booster rollout

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Moderna expects to begin clinical testing of a combination flu/COVID-19 booster shot in 6 to 12 months. AstraZeneca CEO Pascal Soriot said rollouts of COVID-19 boosters are premature. Australia prime minister Scott Morrison is feeling more heat over the country's slow vaccine rollout. Plus more headlines.

PM Tracker

Featured Story

Despite mixed phase 3 showing, Apellis hopes to push eye disorder drug past FDA's finish line

Top Stories

Orchard picks an apple from Novartis' field with new chief technical officer

Louisiana revokes licenses from 7 nursing homes after Ida evacuation failures cost lives

Biogen CEO blames Aduhelm’s rocky launch on 'too much confusion, misinformation and controversy'

Cardiff reveals early data on challenger to Amgen's KRAS crown

Acorda slashes jobs again as generics hamper sales of MS drug

Sanford Health receives $350M for virtual care center to support rural health

COVID-19 tracker: Moderna's combo shot could hit clinic within a year; AZ criticizes booster rollout

Pediatric teletherapy provider DotCom Therapy raises $13M backed by LRVHealth, OSF Ventures

AstraZeneca's COVID-19 shot joins the list of vaccines flagged for rare Guillain-Barre syndrome

Centessa eyes registration in hemophilia as SerpinPC shows reduction of bleeding in phase 2 study

HHS aims to use value-based care payment models to lower drug prices